Pharmaceutical News

RSS

ViroPharma's NDS for Cinryze receives Health Canada's Priority Review status

ViroPharma Incorporated today announced that Health Canada has granted the company Priority Review status for its New Drug Submission (NDS) for Cinryze (C1 inhibitor [human]).

13 Jan 2012

Smart injectable nanotherapeutics could improve treatment for Type I diabetes

A research collaboration between the Wyss Institute for Biologically Inspired Engineering at Harvard University and Children's Hospital Boston has developed "smart" injectable nanotherapeutics that can be programmed to selectively deliver drugs to the cells of the pancreas. Although this nanotechnology will need significant additional testing and development before being ready for clinical use, it could potentially improve treatment for Type I diabetes by increasing therapeutic efficacy and reducing side effects.

13 Jan 2012

Study describes first known case of necrotizing fasciitis from bath salts

A study led by Russell R. Russo, MD, a third-year Orthopaedic Surgery resident at LSU Health Sciences Center New Orleans School of Medicine, has identified a new source of life-threatening necrotizing fasciitis - "bath salts."

13 Jan 2012

Researchers discover previously unknown effect of opioids

A team of researchers at the MedUni Vienna's Department of Neurophysiology has discovered a previously unknown effect of opioids: the study, which has now been published in the highly respected magazine "Science" and was led by Ruth Drdla-Schutting and Jürgen Sandkühler, shows that opioids not only temporarily relieve pain, but at the right dose can also erase memory traces of pain in the spinal cord and therefore eliminate a key cause of chronic pain.

13 Jan 2012

Researchers discover a way to sensitize glioblastoma to chemotherapy

Brain cancer cells are particularly resistant to chemotherapy - toxins enter the cells, but before the toxins can kill, cancer cells quickly pump them back outside. In fact, brain cancer cells are even better than healthy cells at cleaning themselves. This means that when hit with chemotherapy, healthy cells tend to die before brain cancer cells. Especially in the brain, killing healthy cells is bad.

13 Jan 2012

WHO to convene meeting on yaws eradication efforts based on study of oral treatment

"Findings that a one-time oral treatment to cure yaws, a neglected tropical disease, is as effective as the currently recommended penicillin injection have prompted the World Health Organization (WHO) to convene a meeting on how the disease may be wiped out," IRIN reports.

13 Jan 2012

AICAR might protect against heat stress in MH-susceptible individuals

Malignant hyperthermia (MH) is a life-threatening genetic muscle disorder, most commonly triggered in those at risk by certain types of drugs used during anesthesia. Heat stroke, on the other hand, most commonly occurs in individuals in response to physical exertion in hot/humid environments. While their common triggers may differ, the signs associated with MH and heat stroke are remarkably similar - uncontrolled muscle contractions, dangerous increases in body temperature, and muscle breakdown leading to the release of toxins in the blood which may cause cardiac arrhythmias and death. Immediate treatment for these conditions is crucial.

13 Jan 2012

Non-toxin vaccine shows promise against lethal anthrax infection

Vaccination with the anthrax capsule-a naturally occurring component of the bacterium that causes the disease-protected monkeys from lethal anthrax infection, according to U.S. Army scientists. The study, which appears in the Jan. 20th print edition of the journal VACCINE, represents the first successful use of a non-toxin vaccine to protect monkeys from the disease.

13 Jan 2012

ISU receives U.S. patent for phytol-derived adjuvant

While conducting research on cancer, Swapan Ghosh and a team of graduate and doctoral students discovered a phytol-derived adjuvant. That adjuvant formula just became U.S. Patent No. 8,088,395.

13 Jan 2012

Kedem commences development of Gleevec to treat CML in children and adults

Kedem Pharmaceuticals Inc., a specialty pharmaceutical company with focus on sublingual drug delivery system is pleased to announce that has initiated the development of Gleevec.

12 Jan 2012

Study shows how new electronic medication management system reduces drug administration errors

Errors in administration of medication are a serious problem in long-term residential care. New research completed by the University of Warwick and the University of the West of England, Bristol (UWE) shows how a new electronic medication management system developed in the UK specifically for use in residential and nursing homes, has been shown to significantly reduce drug administration errors.

12 Jan 2012

Trends in compulsory licensing of pharmaceuticals since Doha Declaration

In this PLoS Medicine research article, Reed Beall and Randall Kuhn of the Josef Korbel School of International Studies at the University of Denver provide an analysis of trends in compulsory licensing (CL) of pharmaceuticals since the Doha Declaration.

12 Jan 2012

Caltech researchers devise new method to make complex molecules

A team of researchers at the California Institute of Technology (Caltech) has devised a new method for making complex molecules. The reaction they have come up with should enable chemists to synthesize new varieties of a whole subclass of organic compounds called nitrogen-containing heterocycles, thus opening up new avenues for the development of novel pharmaceuticals and natural products ranging from chemotherapeutic compounds to bioactive plant materials such as morphine.

12 Jan 2012

Nature journal publishes Ember's brown fat biology data

Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key data supporting its lead brown fat biology program in the journal Nature.

12 Jan 2012

Amarantus receives U.S. patent titled, 'Dopaminergic Neuronal Survival-Promoting Factors and Uses Thereof'

Amarantus BioSciences, Inc., a biotechnology company developing MANF, a first-in-class disease-modifying therapeutic protein, today announced U.S. Patent Number 8,084,425 has been issued for MANF entitled, Dopaminergic Neuronal Survival-Promoting Factors and Uses Thereof.

12 Jan 2012

Chemotherapy drugs can lead to relapse of leukemia

The chemotherapy drugs required to push a common form of adult leukemia into remission may contribute to DNA damage that can lead to a relapse of the disease in some patients, findings of a new study suggest.

12 Jan 2012

Omega-3 can protect nerves from injury and help them to regenerate

Research from Queen Mary, University of London suggests that omega-3 fatty acids, which are found in fish oil, have the potential to protect nerves from injury and help them to regenerate.

12 Jan 2012

USPTO issues patent to Unigene's peptide-based therapeutics for obesity

Unigene Laboratories, Inc., a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that it had been granted U.S. Patent No. 8,076,291 from the United States Patent and Trademark Office.

11 Jan 2012

Nicotine patches may help individuals with early memory loss

Star Scientific, Inc. - A study released in the January 9th issue of the Journal of Neurology suggests that nicotine patches may help individuals with early memory loss.

11 Jan 2012

Spherix completes SPX-106 28-day rat toxicology study

Spherix Incorporated – an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today reported the successful completion of its 28-day rat toxicology study of its drug candidate, SPX-106.

11 Jan 2012